Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.61 |
| ▸ | ALB | P02768 | 2/20 | 0.60 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HTRA2 | O43464 | 6/20 | 0.54 |
| ▸ | HTRA1 | Q92743 | 6/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.50 |
| ▸ | OXTR | P30559 | 1/20 | 0.50 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13327114 | 0.93 | FOLH1 (0.53) | FOLH1ALBSLC5A2ESR1USP2 | |
| SCHEMBL3289756 | 0.92 | FOLH1 (0.62) | FOLH1ALBSLC5A2ESR1USP2 | |
| SCHEMBL16295184 | 0.88 | FOLH1 (0.68) | FOLH1ALBSLC5A2ESR1USP2 | |
| SCHEMBL22384710 | 0.88 | FOLH1 (0.63) | FOLH1ALBSLC5A2ESR1USP2 | |
| SCHEMBL21476997 | 0.87 | FOLH1 (0.61) | FOLH1ALBSLC5A2ESR1USP2 | |
| SCHEMBL14820144 | 0.86 | FOLH1 (0.59) | FOLH1ALBSLC5A2ESR1USP2 | |
| SCHEMBL13287065 | 0.86 | USP2 (0.60) | FOLH1ALBSLC5A2ESR1USP2 | |
| SCHEMBL3289758 | 0.86 | ALB (0.55) | FOLH1ALBSLC5A2ESR1USP2 | |
| SCHEMBL15130552 | 0.85 | USP2 (0.62) | FOLH1ALBSLC5A2USP2L3MBTL1 | |
| SCHEMBL10035688 | 0.84 | FOLH1 (0.58) | FOLH1ALBSLC5A2ESR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910698-B2 | NPC1L1 orthologues | SCHERING CORPORATION (US) | 2011-03-22 | — | — | US | disclosed |
| US-7723020-B2 | Use of azetidinone compounds | SCHERING CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090098128-A1 | NPC1L1 orthologues | MERCK SHARP & DOHME CORP. | 2009-04-16 | — | — | US | disclosed |
| US-20070105141-A1 | Use of azetidinone compounds | SCHERING CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105141-A1 | Use of azetidinone compounds | NPC1L1, NPC1, CYP46A1 | FOLH1 2500/4885ALB 2759/4885SLC5A2 1050/4885 |
| US-20090098128-A1 | NPC1L1 orthologues | NPC1L1, NPC1, CETP | FOLH1 1671/4885ALB 4289/4885SLC5A2 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.